{"id":"W2895870246","doi":"10.1186/s40425-018-0420-0","title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Pazopanib; Nivolumab; Sunitinib; Renal cell carcinoma; Tolerability; Discontinuation; Adverse effect; Internal medicine; Clinical endpoint; Oncology; Peripheral edema; Urology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002165051,0.0006600596,0.001325783,0.0002811516,0.0002796844,0.0008126523,0.0006446652,0.0008794177,0.001381268],"category_scores_gemma":[0.001002386,0.0002611131,0.001217238,0.0002987333,0.0003654745,0.0003725304,0.0002787428,0.00135727,0.0003186119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008155921,"about_ca_system_score_gemma":0.0009339249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007478277,"about_ca_topic_score_gemma":0.001728797,"domain_scores_codex":[0.9994805,0.0002763725,0.000031248,0.00007941642,0.00009427498,0.00003819541],"domain_scores_gemma":[0.999163,0.0001689931,0.0002556403,0.00007108217,0.00006467837,0.0002765834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6551614,0.02702121,0.07376736,0.001513091,0.008250867,0.0005173732,0.0002926743,0.004881903,0.05189932,0.0001606336,0.005135499,0.1713988],"study_design_scores_gemma":[0.3618235,0.4472198,0.1551079,0.0001160684,0.005325646,0.001260611,0.00007104487,0.004820218,0.01470851,0.0001572928,0.009310246,0.00007915191],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945318,0.003194704,0.0001825689,0.0001342113,0.00003198144,0.000256391,0.0005789186,0.00002778749,0.00106171],"genre_scores_gemma":[0.996309,0.001213095,0.000297936,0.0002469571,0.00006983631,0.0001692546,0.001124192,0.00000982683,0.0005599282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002165051,"threshold_uncertainty_score":0.01144999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02981774737536692,"score_gpt":0.3328356411832563,"score_spread":0.3030178938078893,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}